Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
about
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesIn vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage productsNMR studies of the aggregation of glucagon-like peptide-1: formation of a symmetric helical dimer.Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum.[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.Systemic delivery of bioactive glucagon-like peptide 1 after adenoviral-mediated gene transfer in the murine salivary gland.A potent α/β-peptide analogue of GLP-1 with prolonged action in vivo.Gastric emptying in diabetes: clinical significance and treatment.Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.Expression of human globular adiponectin-glucagon-like peptide-1 analog fusion protein and its assay of glucose-lowering effect in vivoGlucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db MiceRegulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides.The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.The GLP-1 system as a therapeutic target.Glucagon-like peptide 1 (GLP-1) and metabolic diseases.An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain.Potential of liraglutide in the treatment of patients with type 2 diabetes.Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog.Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.The structure and function of the glucagon-like peptide-1 receptor and its ligandsThe effect of glucagon-like peptide 1 on cardiovascular risk.Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.Structural aspects of gut peptides with therapeutic potential for type 2 diabetes.Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.Antidiabetic agents: past, present and future.Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.Controlled release of biologics for the treatment of type 2 diabetes.Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
P2860
Q26778608-3C6AC72C-CE7B-4E40-BB94-C69811B20780Q28067465-D456C0A7-488D-40F7-A078-9BDEBC6B1754Q28543699-32E0AF64-5B72-48F1-8790-783B12A3C6BAQ30686627-81AA1AE8-8491-4ADB-9A68-8C5A9376A617Q33184111-929F273A-2895-4012-8C8F-0CAD57A34181Q33194892-7853B8F1-B38C-4FCF-A0AF-E4DC634490CAQ33786150-22CE2192-591C-43F0-8463-671FF792D9FDQ34026346-285B6162-FD98-470D-85E2-3010B2F4F9BCQ34132297-F9E4A93F-6A84-4FDD-B88D-A11A53A5D8A5Q34282783-8FBE779A-9192-49B7-A189-A1AEF06F13F9Q34579697-C385F260-C2D6-4A18-9E3C-5A50C9608891Q34598940-B47B0694-8140-4D02-9CDF-D0792F0BAAB5Q34648270-3D9AF390-147C-4413-A01F-FD260221B989Q35087846-4D177744-B1D0-4221-99D1-04AC7FB9BB22Q35189265-AE33EB82-8E22-47E0-B96D-7819396F2D89Q35962745-07B9E45D-E527-4EBA-98ED-3F9B14E83166Q36006629-3A635FD6-EF35-438A-94C0-BAAB30ECD904Q36049852-CBA813DE-3515-4A71-BAE9-B747906050FAQ36187070-B4E9DD69-4BFD-4408-8CCA-49BA2CC09207Q36265221-76089226-7774-4FFB-AAF6-6C2E91CB5E1DQ36309183-03BA5B1C-3A78-4A3F-8B09-2B7FB3DAFE77Q37427453-24C94C4B-E022-4BF3-B2AD-1C670AE41C91Q37479037-B89A60E8-C2A9-4D1B-B2A5-FADEEDD6BD6FQ37641326-C509E111-E409-435D-BCF2-700E72A77BC0Q37852801-F68237F6-0B6E-4C34-A41A-A76A1F02B4B2Q37939244-13615DE0-0039-44D8-9269-440C887750DDQ37980019-DA415CF2-3426-4999-B5BE-108016D0AFF3Q38016154-D482DE0F-F86A-4BA4-8EED-1B5067000AC9Q38071991-7CF89B2C-7B09-4956-9DE9-FCCA465E7A1EQ38078816-7D6914BB-AC5A-4A7D-AEB4-4C90E80811FCQ38089737-AB4DADD2-8147-48DC-9EB4-2B4EE3980D96Q38342150-FE148520-7113-4702-938A-FF878CF45B7AQ38346050-EF167AFC-B8CB-4003-9213-D06F459B4B95Q38363899-95F234DC-8924-400E-8F28-33E295E8D074Q38665753-EF2DB6D3-B012-4D2A-B6BD-352860767B94Q38838461-70E45E87-0054-4014-9D5F-4B7393D481B2Q39887914-920F0DB1-E18C-4BC8-BF71-79E6626C200EQ40035788-4EBED8C3-9BB2-4A80-BA5A-7130A2F1C088Q40116671-22438277-7641-42AA-A8DC-61A55AC32B7EQ40404408-5E5B2D2C-D1D4-428E-B793-1331D1DCABD9
P2860
Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Dipeptidyl peptidase IV resist ...... improved biological activity.
@en
type
label
Dipeptidyl peptidase IV resist ...... improved biological activity.
@en
prefLabel
Dipeptidyl peptidase IV resist ...... improved biological activity.
@en
P2093
P356
P1433
P1476
Dipeptidyl peptidase IV resist ...... improved biological activity.
@en
P2093
C F Deacon
F C Wiberg
L B Knudsen
O Jacobsen
P2888
P304
P356
10.1007/S001250050903
P577
1998-03-01T00:00:00Z